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Abstract 
      The basal ganglia are a highly interconnected 
group of subcortical nuclei in the vertebrate brain 
that play a critical role not only in the control of 
movements but also in some cognitive and behavioural 
functions. Several recent studies have emphasized that 
serotonergic pathways in the central nervous system 
(CNS) are intimately involved in the modulation of the 
basal ganglia and in the pathophysiology of human 
involuntary  movement                  disorders.  These  observations
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are supported by anatomical evidence demonstrating large serotonergic 
innervation of the basal ganglia. In fact, serotonergic terminals have been 
reported to make synaptic contacts with both dopamine (DA)-containing 
neurons and γ-aminobutyric acid (GABA)-containing neurons in the striatum, 
globus pallidus, subthalamus and substantia nigra. These brain areas contain 
the highest concentration of serotonin (5-HT), with the substantia nigra pars 
reticulata receiving the greatest input. Furthermore, in these structures a high 
expression of 5-HT different receptor subtypes has been revealed. In this 
paper, evidence demonstrating the serotonergic control of basal ganglia 
functions will be reviewed, focusing on the role of the 5-HT2C receptor 
subtype. Moreover, the involvement of 5-HT2C receptors in neurological 
disorders such as Parkinson’s diseases and other related motor disorders, and 
their management with drugs acting on 5-HT2C receptor will be discussed. 
 
Introduction 
 Since the 1950s, when serotonin (5-HT) was discovered in the mammalian 
central nervous system (CNS), an enormous amount of experimental evidence 
has revealed the pivotal role of this biogenic amine in a bewildering diversity of 
behavioural and physiological processes. This is not surprising, considering the 
almost ubiquitous distribution of 5-HT-containing axon terminals throughout the 
CNS, although 5-HT is synthesized by a small group of neurons within the raphe 
nuclei of the brain stem. Despite this broad axon-terminal domain of 5-HT 
neurons, a closer examination reveals a preferential targeting of motor areas in 
the CNS [1]. For example, in the rat there is a very dense innervation of the 
ventral horn of the spinal cord, the motor nucleus of the trigeminal, the facial 
motor nucleus and all components of the basal ganglia circuitry [2]. It is thus 
likely that 5-HT plays a role in regulating the appropriate selection of voluntary 
movements by the basal ganglia and abnormalities in 5-HT transmission might 
contribute to the neural mechanisms underlying disorders of basal ganglia origin, 
such as Parkinson’s disease (PD), and the treatment complications of such 
disorders, for example levodopa-induced dyskinesia. Indeed, biochemical 
evidence suggests that 5-HT transmission is abnormal in the basal ganglia of 
patients with PD [3]. Moreover atypical antipsychotic drugs (APDs) with affinity 
for 5-HT2  receptors have less motor side-effects [4]. 
 During the last decades, advances in the understanding of receptors 
mediating the effect of 5-HT have represented one of the success stories of 
neuropharmacology. Many of the 5-HT receptors are found within the basal 
ganglia and are most likely involved in the modulation of basal ganglia 
circuitry and in the pathology of their correlated disorders. Of particular 
interest with respect to the development of new treatments for PD and other 
motor disorders is the 5-HT2C receptor subtype. This will be the subject of further  
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discussion in the remainder of this review. First, the anatomical and 
physiological organization of basal ganglia and the 5-HT system will be briefly 
summarized. Thereafter, several aspects of 5-HT2C control of pathophysiology 
of basal ganglia nuclei will be discussed. 
 
Overview of basal ganglia anatomy and functions 
 The basal ganglia are the largest subcortical nuclei of vertebrate brain 
including human forebrain, and they are placed in a key position to influence 
motor behaviour, emotions, and cognition [5]. Even the understanding of the 
basal ganglia circuits still must be considered as highly incomplete, although 
knowledge has grown rapidly during the last decades. The model presented 
here is simplified and mainly limited to the aspects most relevant to the 
discussion [6,7]. The basal ganglia in the vertebrate brain consist of several 
different nuclei (Fig. 1), the striatum (ST), the globus pallidus (GP) and  its 
equivalent in primates, the external segment of the globus pallidus (GPe), the 
entopeduncular nucleus (EP) and its equivalent in primates, the internal 
segment of the globus pallidus (GPi), the subthalamic nucleus (STN) and the 
substantia nigra (SN) and each of these is profoundly important clinically [8]. 
 
 Recently, it has been suggested that the pedunculopontine nucleus (PPN) 
of the brainstem should be considered as part of the basal ganglia as well 
[9,10]. Indeed, it is anatomically and physiologically associated with them and 
affects the function of several nuclei in the basal ganglia circuits [9,10].  
 
 The striatum (or caudate-putamen) is the main input nucleus, which 
receives topographical excitatory projections from almost the entire cerebral 
cortex, especially from the sensorimotor and frontal cortex [11]. The striatum 
and the downstream structures in the basal ganglia are organised in 
topographically and functionally segregated pathways. The cortical inputs to 
the striatum are convergent, in such a way, for example, that sensory and 
motor cortex areas converge into single striatal zones [12]. Close to the 
striatum is located the GPi and the substantia nigra pars reticulata (SNr), the 
main output nuclei of the basal ganglia [13]. They project, via various thalamic 
nuclei, to most cortical areas of the frontal lobe [14]. This architecture means 
that the basal ganglia are part of extensive loops, basal ganglia-thalamocortical 
circuits, which link almost the entire cerebral cortex to the frontal lobe. The 
GPi and the SNr also have descending output to the brain stem, especially with 
the PPT nucleus. Through this pathway the basal ganglia can influence brain 
stem functions like the inhibition of auditory input [15]. The striatum can be 
divided into three main parts: the putamen, the caudate nucleus, and the ventral 
striatum. This division roughly corresponds to a functional division of basal 
ganglia-thalamocortical circuits: (sensori)motor circuits of the putamen, with output  
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Figure 1. Schematic diagrams of the circuitry of basal ganglia in rodents under normal 
(left) and hypothetical Parkinsonian conditions (right). The classical model is 
completed with the presence of the dorsal raphe nucleus (DRN) and its projections to 
the different basal ganglia nuclei (in grey). Inhibitory projections are shown as black 
dashed arrows, excitatory as black normal arrows. The presence of the 5-HT2C receptors 
is indicated by dots in the relative boxes of the diagram, the concentration of dots 
indicates the amount of expression. The absence of 5-HT2C receptors is shown by 
empty boxes enclosed with a double line. In the pathological condition, thin lines are 
pathways with reduced activity; medium lines are physiologically normal pathways; 
thicker lines are over-active pathways implicated in Parkinson’s disease. For further 
details see the main text. Abbreviations: GP, globus pallidus; SNc, substantia nigra pars 
compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; EP, 
entopeduncular nucleus; PPN, pedunculopontine nucleus; HBN, lateral habenular 
nucleus; SC, superior colliculus; PR, parvicellular reticular formation. 
 
to  primary  motor  cortex, the     supplementary motor cortex (SMA), and the 
premotor cortex; associative circuits of  the  caudate nucleus, with output to the 
prefrontal cortex; and limbic circuits of the ventral striatum, with output to the 
anterior cingulate cortex and medial prefrontal cortex [11,13]. The ventral 
(limbic) striatum also receives input from limbic structures, such as the 
amygdala and hippocampus [16]. The striatum projects to the output structures 
(GPi and SNr) by two pathways, the so-called direct and indirect pathways. 
The indirect pathway also includes the STN. All the projections from the 
striatum, the GPe, the GPi and SNr release GABA and are inhibitory, while the 
projections from the cortex, the STN and the thalamus are excitatory, and use 
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glutamate as their neurotransmitter. The GABA-conteining neurons in the GPi 
and the SNr are tonically active, they project to the ventral tier of thalamus 
(ventrolateral, ventromedial, ventral anterior nuclei) and form inhibitory synaptic 
contacts with thalamocortical neurons that project to the motor and premotor 
cortex. Activation of the direct pathway inhibits GPi/SNr neurons, which in turn 
disinhibits thalamic neurons, finally resulting in excitation of the cortical neurons. 
Activation of the indirect pathway has an opposite effect, activating the GPi/SNr 
and thereby inhibiting the cortex [13]. In this way, the two pathways balance each 
other, modulating cortical activity. Alexander and Crutcher [17] suggested a model 
where the indirect pathway provides a diffuse background inhibition of 
behavioural impulses, while the direct pathway gives a focused activation of the 
desired behavioural program. In this model, the basal ganglia play an important 
role in inhibiting potentially competing motor programs. This may be a general 
mechanism for action selection where “the winner takes all”, by facilitation of the 
strongest cortical signal and suppression of the rest [18]. Recently, it has been 
proposed by Wilkström and co-workers that the basal ganglia can also elicit a 
behaviourally meaningful and varied motor pattern without the involvement of the 
cerebral cortex [19]. Among the basal ganglia nuclei, the striatum seems to have a 
prominent role in determining when a given motor program should be selected and 
called into action. For the hypothesised function of the striatum in selection of 
motor programs, a certain level of tonic dopamine (DA) activity is required. 
Dopamine projections from the substantia nigra pars compacta (SNc) to the 
striatum modulate the activity of striatal neurons in a complex way. According to a 
simplified model, the striatal neurons forming the direct pathway mainly express 
excitatory D1-receptors, while the striatal neurons in the indirect pathway mainly 
have inhibitory D2-receptors. This means that DA would facilitate motor 
behaviours through the activation of the direct pathway and conversely through 
the inhibition of the indirect one. Reduced DA innervation of the striatum 
results, indeed, in hypokinesia and difficulty in initiating different motor 
patterns, including facial expression [20], enhanced striatal DA activity will 
instead give rise to hyperkinesia (i.e. premature or unintended activation of 
motor programs). Dopamine also seems to be involved in basal ganglia 
learning processes, by strengthening or weakening the efficacy of 
corticostriatal synapses [6,21,22]. In this way the striatum may learn to 
respond to certain patterns of cortical activation. 
 
Serotonin innervation of basal ganglia  
 More than fifty   years have passed since Twarog and Page [23] isolated an 
indole, identified as serotonin (5-HT), in the mammalian brain. Subsequently, 
Brodie and colleagues [24] suggested that 5-HT  might serve as a neuro-
transmitter in the central nervous system (CNS). 
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 In vertebrates, the majority of the neurons containing 5-HT are grouped in 
9 nuclei named B1 to B9, located in the medial part of the brainstem, 
generically called the raphe nuclei [25] (Fig. 2). These midline clusters can be 
divided into two major groups. The caudal or inferior group, localized in the 
medulla, contains the three nuclei projecting essentially to the grey matter of 
the spinal cord: the nucleus raphe magnus (NMR, cell group B5), nucleus 
raphe obscurus (NRO, cell groups B1-B2-B3), and nucleus raphe pallidus 
(NRP, cell group B4). The rostral or superior group, located in the 
pons/mesenchepalon, contains the dorsal raphe nucleus (DRN, cell groups B6 
and B7) and the medial raphe nucleus (MRN, cell group B8).  
 These nuclei supply about 80% of the serotonergic innervation to the 
forebrain. Even if in many brain areas, the innervation coming from the two 
nuclei overlaps, in certain regions the innervation comes exclusively or pre-  
valently  from  one  nucleus  only. For example, the dorsal hippocampus receives 
a serotonergic innervation only         from MRN, other areas innervated  preferentially  
 
 
 
Figure 2. Midsaggital view of the rat brainstem with serotonin-immunoreactive cell 
body groups. The blue and red ovals encompass the two major subdivisions of the brain 
serotonergic system. Abbreviations: DRN, dorsal raphe nucleus; MRN, medial raphe 
nucleus; NRM; nucleus raphe magnus; NRO, nucleus raphe obscurus. Cell groups B1 
to B9 according to the terminology of Dahlström and Fuxe [25]. 
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from this nucleus are: the medial preoptic area, the suprachiasmatic nucleus, the 
olfactory bulb and the medial septum nucleus. The dorsal raphe nucleus innervates 
all the basal ganglia circuitry (Fig. 1), sending projections to the corpus 
striatum, the GP, the STN, SN and the PPN, and provides most of the 
innervation of the prefrontal cortex, including the motor cortices. Serotonin-
containing cell bodies of the raphe send projections to both dopaminergic and 
GABAergic cells in the substantia nigra (SN), and to their terminal fields [26-
29]. Moreover, electron microscopy demonstrates the presence of synaptic 
contacts of [3H]5-HT labeled terminals with both dopaminergic and non-
dopaminergic dendrites in the SN pars compacta and reticulata [9,26,29]. The 
DRN innervates, together with the MRN the ventral part of the hippocampus, 
the nucleus accumbens and various nuclei of the thalamus among them the 
ventral lateral nuclear group that processes motor information and the 
hippocampus [31-33]. Moreover, extensive serotonergic connections between 
the DRN and the MRN also exist [34]. 
 
Serotonin2C receptor and its distribution within the 
basal ganglia nuclei 
Serotonin2C receptors  
 The first evidence for the existence of multiple subtypes of 5-HT receptors 
was provided by Gaddum and Picarelli who discovered the so-called M and D 
receptors [35]. Definitive evidence for two distinct recognition sites was reported 
by Peroutka and Snyder [36] who classified 5-HT in two subtypes 5-HT1 or 5-
HT2 depending on their affinity to [3H]-5-HT and [3H]-spiperone, respectively. A 
vast amount of research has led to the discovery and characterisation of a 
plethora of 5-HT receptor subtypes. At present, seven classes of 5-HT receptors 
(5-HT1-7 receptors) have been identified which comprise at least a total of 15 
subtypes [37] (Table 1). Not surprisingly, with so many potential targets, 
distributed throughout all the CNS, 5-HT is a major neurotransmitter involved in 
a such large number of physiological and pathological processes. 5-HT receptors 
are cell surface receptors that have been classified on the basis of their 
pharmacological responses to specific ligands, sequence similarities at the gene 
and amino acid levels, gene organisation, and second messenger coupling 
pathways [37,38]. Except for the 5-HT3 receptor, which is a ligand gated 
channel, all 5-HT receptors belong to the seven transmembrane domain                 
G-protein-coupled receptor (GPCR) superfamily [37,39,40]. 
 
 Among the multiple classes of 5-HT receptors described in the central 
nervous system [37,38,41], much attention has been devoted to the 5-HT2 
receptor              family since it has been shown by experimental and clinical observation 
that it may represent a possible therapeutic target for the development of drugs 
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Table 1 
 
       Nomenclature and classification of the serotonin receptors subtypes 
Receptor 
Seven-transmembrane-spanning, G-protein-coupled receptors 
Negatively coupled to adenylate cyclase (Gi/o)) 
5-HT1A 
5-HT1B 
5-HT1D 
5-HT1E 
5-HT1F 
Positively coupled to adenylate cyclase (Gs) 
5-HT4 
5-HT6 
5-HT7 
Coupled to phospholipase C (Gq) 
5-HT2A 
5-HT2B 
5-HT2C 
Unknowing coupling 
5-HT5A 
5-HT5B 
Ligand-gated ion channel/receptor 
5-HT3A 
5-HT3B 
5-HT3C 
 
for a range of CNS disorders such as schizophrenia, depression, drug abuse, eating 
disorders, Parkinson’s disease and epilepsy [42-45]. In fact, 5-HT2 receptors are  
major targets for a wide array of psychoactive drugs, ranging from atypical 
APDs, anxiolytics and antidepressants, which have a 5-HT2 antagonistic 
action, to hallucinogens, which are agonists of the 5-HT2 receptors [46-49]. 
The 5-HT2 receptors form a closely related subgroup of G-protein-coupled 
receptors and show the typical heptahelical structure of an integral membrane 
protein monomer. They are currently classified as 5-HT2A, 5-HT2B and 5-HT2C 
subtypes [37,38,41,50], based on their close structural homology, 
pharmacology and signal transduction pathways and they are differently 
localized in the brain [37,38,41,50]. The amino acid sequence of the 5-HT2 
receptors shares a high degree (>70%) of identity within the transmembrane 
segments [37,38,41,50], consequently, it is not surprising that many 
compounds bind with high affinity to all these three receptor subtypes. 
 The 5-HT2C receptor has received less attention in psychopharmacology 
compared to the 5-HT2A sites. This may relate to the inadequacy of techniques 
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to determine the receptor in tissue samples. However, evidence from a variety 
of sources has demonstrated the involvement of this receptor in several 
important physiological and psychological processes including motor function, 
anxiety, ingestive behaviour and brain development [45,51-54]. 5-HT2C 
receptor-deficient mice are overweight as a result of abnormal control of 
feeding behaviour [55,56], thus this receptor could play a role in the 
serotonergic control of appetite. Mutant animals are also prone to spontaneous 
death from seizures, suggesting that receptors of this type mediate tonic 
inhibition of neuronal network excitability. Direct activation of the 5-HT2C 
receptors by agonists in normal rats decreases their food intake, and central 5-
HT systems probably directly activate pro-opiomelanocortin (POMC) neurons 
via the 5-HT2C receptors [57-60]. The 5-HT2C receptor knockout mice are also 
more wakeful, and show several abnormalities in rapid eye movement (REM) 
sleep expression, and enhanced response to sleep deprivation compared with wild-
type control mice. These findings suggest that the 5-HT2C receptors may mediate 
several effects on sleep that have been ascribed to 5-HT [61]. Furthermore, some 
interesting pharmacogenetic observations have focused on the potential importance 
of this receptor for the development of novel antipsychotic, antidepressant, 
antiparkinsonian and antiepileptic drugs [43,44,52]. 
 The 5-HT2C receptor gene is unique among the members of the 5-HT receptors 
family by virtue of its genomic organization. The human 5-HT2C receptor gene has 
been mapped to X-chromosome band q24 [62] and shown to contain six exons and 
five introns. The gene product is a protein of 460 amino acids, heavily glycosylated 
and migrating as a 60-kDa protein [63]. The 5-HT2C receptor is a member of the 
GPCR superfamily with 7-transmembrane spanning domains and three 
intracellular loops connecting them. The 5-HT2C receptor is the only known 
GPCRs whose mRNA undergoes post-trascriptional editing to yield different 
isoforms [64]. Although RNA editing produces at least 14 functional isoforms (and 
potentially many more) of the receptor, these isoforms are associated with a 
variation in the efficacy of their interaction with G protein [65-67]. In this regard, it 
was recently reported that the depletion of 5-HT increases expression of 5-HT2C 
mRNA isoforms encoding receptors with higher sensitivity to 5-HT. This evidence 
suggests that this editing acts as a fine-tuning mechanism that adjusts receptor 
function to changes in synaptic activity, to maintain their normal response 
properties to agonist stimulation [68]. Interestingly, alteration of the 5-HT2C pre-
mRNA editing has been implied in several psychiatric disorders [69] but, to date, 
no evidence exists for its involvement in neurological disorders, even though Fox 
and colleagues have suggested that this could occur in PD [70]. Decreased agonist 
binding affinity has also been linked to RNA editing, however antagonist binding 
remained unaltered [71]. 
 As regards the signalling pathway, agonist binding to the 5-HT2C receptor 
activates phospholipase C (PLC) via G protein (Gq/11) [72-75]. However, other 
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different signalling pathways for the 5-HT2C receptor subtype have been shown. 
Indeed, some agonists binding to the 5-HT2C receptor can instead activate 
phospholipase A2 (PLA2) leading to the release of arachidonic acid (AA) [76]. 
Furthermore, 5-HT2C receptors can also activate phospholipase D (PLD), 
involving Gα13 and free Gβ−γ subunits [77], the mitogen-activated protein kinase, 
and the extracellular signal-regulated kinase (ERK) 1 and 2 [78]. Interestingly, it 
was shown that coupling of 5-HT2C receptors to Gα13 and Gq/11 can be 
differentially stimulated by certain agonists; ergots preferentially stimulates 
Gq/11, whereas 5-HT and RO 600175 are equally efficacious towards both 
pathways. Differential G-protein coupling appears to depend on   receptor 
reserve [79] and is regulated by RNA editing [65,80]. These observations 
suggested that it may be possible to develop agonists which preferentially act in 
specific tissues via a specific signalling pathway. Amongst the 5-HT2 receptor 
family, 5-HT2C appears more prone to exhibit intrinsic constitutive activity. In 
this regard, studies have demonstrated the considerable ability of the native 5-
HT2C receptor to spontaneously activate intracellular signalling pathways, 
including PLC and PLA2, in the absence of agonist stimulation [81-84]. This quite 
peculiar 5-HT2C receptor characteristic occurs not only in recombinant cells but 
also in natural tissues and it seems to play an important role in the tonic control of 
the central dopaminergic function [85,86]. The occurrence of constitutive receptor 
activity allows the detection of compounds that can block this activity, the so-
called inverse agonists [81]. Inverse agonists may show differential 
pharmacological and clinical effects as compared to mere antagonists and bring up 
important therapeutic perspectives [87]. For instance, several atypical antipsychotic 
drugs display inverse agonist activity at constitutive 5-HT2C receptors [86,88].  
 In contrast to most other receptors 5-HT2C is not classically regulated. 
Indeed, 5-HT2C receptors appear not only to decrease their responsiveness upon 
chronic agonist stimulation, but also and paradoxically after chronic treatment 
with antagonists [89,90]. This mechanism appears to be related to an 
internalisation process that removes activated cell surface receptors from the 
plasma membrane involving a phosphorylation step and possible degradation in 
lysosomes [49]. Inasmuch as a large number of psychotropic drugs, including 
atypical antipsychotics, antidepressants, and anxiolytics, can all induce down-
regulation of 5-HT2C receptors, it has been suggested that this alteration plays a 
role in the therapeutic action of these drugs [47,49]. 
 
Serotonin2C receptor in the basal ganglia nuclei 
 Pazos and colleagues first identified the 5-HT2C receptors by radioligand 
binding of 3H-5-HT and 3H-mesulergine in the pig choroid plexus, and initially 
called it 5-HT1C because of its high affinity for tritiated 5-HT [91]. However, 
once  the receptor  was cloned  and more  information  about  its characteristics 
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became available, a shift to the 5-HT2 receptor family and reclassification as 5-
HT2C became accepted. Later studies using autoriadiography with 3H-
mesulergine have confirmed a conspicuously high binding site density in the 
choroid plexus in all mammalian species, including subhuman and human 
primates. High density is also found in the SNr, globus pallidus and ventro-
medial thalamus with low amounts detected in many other brain areas [92-94] 
(Fig. 1). A widespread distribution of 5-HT2C receptor mRNA has been 
demonstrated in rat, monkey and human brains using in situ hybridization 
techniques [95-98]. 5-HT2C receptors are more abundant and more widely 
expressed in the brain than 5-HT2A receptors, although there are several areas 
where both receptors coexist [99]. As was found for 5-HT2C binding sites, the 
choroid plexus also contained the highest amounts of 5-HT2C receptor mRNA 
and protein, mainly associated with choroid epithelial cells [100]. High levels 
of both 5-HT2C protein and mRNA have been found in several cortical areas, in 
the hippocampus, striatum, septal nuclei, thalamic nuclei, midbrain nuclei, 
brain stem nuclei and the spinal cord [95,99,101]. A number of studies have 
concentrated on the localization and potential role of 5-HT2C receptors in the 
basal ganglia and have also revealed marked differences in the distribution of 
this mRNA among subregions of the basal ganglia [96,102,103,104], also its 
level of expression varied markedly within labeled nuclei [104] (Fig. 1). In the 
striatum most labeled neurons were medium-sized, probably, efferent neurons. 
Labeling was not detected in large cholinergic interneurons or in glial cells. 
Neurons that express mRNA for the 5-HT2C receptors were found in discrete 
areas of the caudate-putamen, mostly in the ventral and ventrolateral parts of 
the nucleus. 5-HT2C receptor mRNA did not show a preferential colocalization 
with neuropeptide markers for either the striatonigral pathway (substance P 
and dynorphin) or the striato-pallidal projections (enkephalin). This indicates 
that 5-HT2C expression is not differentially influenced by the two main targets 
to which the striatum projects, and the signal mediated via the 5-HT2C receptor 
is likely to have downstream consequences in both striatal output locations 
showing a substantial difference from the dopaminergic system. Furthermore, 
5-HT2C receptor mRNA is differentially localized with regard to patch/matrix 
striatal structure. In fact, 5-HT2C receptor mRNA occurs almost exclusively in 
the patch compartment areas, [105] revealing a preferential modulation of the 
projection to the SNc and thus the striatal dopaminergic input [106,107]. In the 
striatal target areas, dense labeling is found in the entopeduncular nucleus 
(internal pallidum) while no mRNA is found in the globus pallidus (external 
pallidum), an area where 5-HT2C receptor binding sites have been detected 
(Fig. 1). Therefore, the differential distribution of 5-HT2C receptor mRNA may 
be indicative of differential regulation of the direct and indirect pathways of 
striatal output by 5-HT. The subthalamic nucleus contained large numbers of 
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cells that expressed a high level of 5-HT2C receptor mRNA, where the 
receptors could be involved in the oral dyskinesia that is induced by drugs with 
5-HT2C agonist action [104]. In the SN, neurons labeled for 5-HT2C receptors 
were present in both the SNc and the SNr from rostrocaudal and mediolateral 
levels. Despite an homogenous 5-HT innervation of the SN, the 5-HT2C receptors 
were express in about half of the neuronal population, however, the density was 
markedly higher caudally than rostrally, in both nuclear subdivisions. Receptor 
expression is confined to GABAergic neurons and not to dopaminergic cell bodies. 
Other immunoistochemical and electrophysiological studies [28,108-110] have 
corroborated this piece of evidence suggesting an indirect control of dopaminergic 
transmission via 5-HT2C receptors and a preferential effect on SNr GABAergic 
projecting neurons as compared to SNr GABAergic interneurons (Fig. 3).  
 The distribution of 5-HT2C receptor mRNA-expressing cells does not 
present any obvious similarity with the lamellar distribution of neurons 
projecting to different sets of target structures [111]. However, the much larger 
number of neurons expressing the 5-HT2C receptor mRNA in the caudal part of 
the SNr raises the possibility that this receptor may be preferentially associated  
 
 
 
Figure 3. Schematic drawing showing the distribution of 5-HT2C receptors throughout 
the rat substantia nigra according to Di Giovanni et al. [110]. Dopaminergic neurons of 
the dorsal pars compacta do not express the 5-HT2C receptor; in the par reticulata the 5-
HT2C receptors are present essentially on GABAergic projecting neurons and probably 
not on presumed GABAergic interneurons. Abbreviations: GABA, γ-aminobutyric acid; 
SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata. 
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with neurons projecting to the tegmentopontine nucleus, which are more 
abundant in the caudal than in the rostral pars reticulata [111]. However, this 
hypothesis is too simplistic if we take in to consideration the complexity of collateral 
projections of SNr neurons that could influence neurons located in other 
regions within the nucleus [104,110].  
 
Serotonin2C modulation of basal ganglia circuitry 
Serototnin2C modulation of dopaminergic nigrostriatal pathway 
 The precise role of 5-HT in the SNc has not yet been firmly established, 
although some evidence indicates a possible inhibitory role for 5-HT over the 
SNc neurons, mainly supported by studies involving electrical stimulation of 
the DRN [112-115] and microionthophoretic application of 5-HT on SNc DA 
neurons [116,117]. However, 5-HT itself has been shown to increase the firing 
rate of SNc DA neurons in vitro [118] and to facilitate a voltage-dependent 
calcium conductance [119].  
       The involvement of 5-HT2C receptor subtypes in the control of 
mesencefalic DA neurons activity is now well established [52,86,110,120-
128], and evidence has been provided that it exerts both tonic and phasic 
modulation of DA function [85,123-131]. Furthermore, some studies carried 
out in our laboratory have shown a noteworthy preferential control of the 
mesorticolimbic compared to the nigrostriatal DA pathway by the 5-HT2C 
receptor subtype, this evidence has also been confirmed by Tecott and 
colleagues [132]. Indeed, firstly we showed that selective serotonin reuptake 
inhibitors (SSRIs) reduce the spontaneous activity of midbrain DA neurons, by 
acting on 5-HT2C receptors, in the VTA but not in the SNc [133,134]. In 
addition, there is the evidence that 5-HT2C receptor agonists mCPP, MK212 
and RO 600175 and the selective antagonist SB 242084 neither significantly 
affect the activity of SNc DA-containing neurons nor the in vivo DA release in 
the striatum [38,135-137]. Lastly, the mixed 5-HT2C/2B receptor antagonist SB 
206553 caused only a slight increase in the basal activity of DA neurons in the 
SNc and in the striatal DA release [138]. Consistently, it has been reported that 
the new selective antagonist SB 243213 does not significantly alter the basal 
firing rate or pattern of SNc neurons while its repeated administration modifies 
only the pattern discharge but not the number of spontaneously active SNc DA 
cells [139]. Nevertheless, another group did not find this decrease in sensitivity 
of the nigrostriatal DA system following the acute administration of 5-HT2C 
ligands [140]. It is worth noting, that these authors also showed that SB 
206553 elicited a dose related increase in striatal DA release behaving as a 5-
HT2C inverse agonist in vivo. Indeed, they found that SB 242084 prevented the 
SB 206553-induced increase and reversed the RO 600175-induced decrease in  
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DA release in the striatum [86]. The discrepancy between these data and our 
evidence is unknown. In spite of a lack of a local effect on DA cell bodies, the 
5-HT2C receptors located on the nerve terminal regions seem to play a role in 
the regulation of DA release. Indeed, local administration of the antagonist SB 
206553 increased DA efflux in the striatum and this effect was attenuated by 
systemic administration of the agonist mCPP [128].  
 
Serotonin2C modulation of striatal activity 
      In agreement with anatomical data, most of the reports on this subject 
indicate that striatal cells are predominantly affected by dorsal raphe stimulation, 
the median raphe stimulation being unable to alter striatal cell activity directly 
[141,142]. In addition, it has been found that suppression of spontaneous firing 
activity is the main response of striatal cells following dorsal raphe stimulation, 
excitation being observed in only about 10% of them. Nevertheless, a rebound 
excitation was observed in some cells that were initially inhibited. All these 
changes were rapid in onset and prevented by methesergide, a 5-HT2 antagonist 
[141,142]. Local application of 5-HT was found to produce similar changes to 
that caused by raphe stimulation and most of the cells responsive to the raphe 
stimulation were also affected by nigral stimulation [142]. The data obtained by 
Blier and colleagues [143] concerning single-unit recordings coupled with 
microiontophoresis in vivo, in rats, guinea pigs and in 5-HT2C receptor mutant 
mice, are consonant with the hypothesis of an inhibitory action of the 5-HT 
system on the neuronal activity of the striatum. These authors reported that in the 
caudate nucleus the inhibitory effect of 5-HT was mimicked by the 5-HT2C 
receptor agonist mCPP [143,144]. Furthermore, significantly less quisqualate 
was required to activate neurons in the caudate nucleus of mutant mice than in 
the wild-type mice, suggesting that 5-HT2C receptors serve a tonic inhibitory role 
in membrane excitability [145]. In concordance with these electrophysiological 
findings, there is the behavioural evidence that caudate injections of 5-HT 
provoked contraversive turning, conversely intracaudate methysergide induced 
ipsiversive circling [146]. These data are compatible with 5-HT having a tonic 
inhibitory function in the striatum. In addition, the facilitation by hyoscine and 
the attenuation by eserine of the 5-HT induced contraversive circling, together 
with the converse effects of these drugs on methysergide-evoked ipsiversive 
rotations, are consistent with raphe-caudate 5-HT fibres synapsing directly with, 
and inhibiting, striatal cholinergic neurons. Given that motor behaviour recruits 
multiple striatal neurotransmitter systems, recent attention has focused on the 
interaction between DA and 5-HT receptors. In the intact striatum, several 
studies have consistently demonstrated that intrinsic 5-HT2 receptors can modify 
DA function, and have postulated divergent roles for 5-HT2A and 5-HT2C 
receptor subtypes [123,147]. 5-HT2A antagonists reduce hyperlocomotion 
induced by cocaine, amphetamine and 3,4-methylenedioxymethyamphetamine  
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(MDMA) [148,149], whereas, 5-HT2C receptor antagonists have been shown to 
enhance or reduce these effects depending upon which compounds and 
neuronal sites are studied [150-152]. Recent studies from Walker’s group have 
shown that following DA depletion D1-induced locomotor activity can be 
reduced by antagonism of striatal 5-HT2A, but not 5-HT2C receptors [153]. This 
preferential involvement of the 5-HT2A subtype is confirmed by the evidence 
that intrastriatal injections of the selective 5-HT2C antagonist RS 102221 had 
no effect on motor activity, conversely the 5-HT2A agonist DOI induced motor 
behaviour in neonate 6-OHDA-lesioned rats which was attenuated by the 5-
HT2A receptor antagonism [154].  
      However, using intracellular recording techniques, Kitai and co-workers 
[155] found that dorsal raphe stimulation was consistently capable of generating 
excitatory postsynaptic potentials. These findings were subsequently repeated in 
the Kitai laboratory, and it was indicated that non-5-HT dorsal raphe-striatal 
neurons could be involved in striatal responses to 5-HT. They also showed that 
the increase of the firing frequency in rat neostriatal medium-spiny neurons 
induced by 5-HT depended on reducing voltage-dependent potassium currents 
[156,157]. A recent in vivo study showed a consistent excitation of the striatal 
neurons induced by microintophoretical application of 5-HT while the mixed 
agonist 5-HT2A/2C DOI caused a preferential inhibitory response, highlighting 
varying effects of different 5-HT receptor subtypes [158].  
 Interestingly, recent pharmacological data and lesion studies have established 
that the biosynthesis of neuropeptides in the striatum is regulated by the 5-HT 
innervation originating from the dorsal raphe suggesting that 5-HT in the striatum 
might exert a metabolic regulatory function on the biosynthesis of neuropeptides 
rather than acting as ion channel modulator [159,160]. 
 
Serotonin2C modulation of substantia nigra pars reticulata 
activity 
 The SNr neurons receive the largest 5-HT innervation from the DRN of all 
brain regions [161,162], and express a high level of 5-HT2C receptors which 
are post-synaptic and locatedon the somato-dendritic region of SNr neurons. It 
has been calculated that the density of 5-HT-immunoreactive varicosities in the 
SNr is in the order of 9x106/mm3, of which about 74% form synaptic 
specializations with GABAergic projection neurons [163]. This picture gives 
an idea of the great influence that 5-HT could exert on the activity of SNr 
neurons. Early studies have revealed a primarily inhibitory action of serotonin 
on SNr neurons. Electrical stimulation of the DRN caused mostly inhibitory 
responses in the SNr, as measured by single-unit extracellular recording in 
vivo [161]. Similarly, the iontophoresis of 5-HT into the SN produced mixed, 
although mostly inhibitory, effects in the SNr [164,116]. The inhibition of SNr  
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neurons by 5-HT was supported by the finding that unilateral injection of 5-HT 
into the SNr induced controlateral circling, as did muscimol [165]. Bilateral 
injection of 5-HT into the SNr increased vacuous chewing movements (a model of 
drug-induced dyskinesia) [166], mimicking another of the behavioural effects of 
intranigral muscimol. Furthermore, the bilateral intranigral injection of fluoxetine 
was anticonvulsant in an animal model of epilepsy. In spite of this evidence, Lacey 
and co-workers have shown, by using in vitro electrophysiological methods, that 5-
HT not only excites SNr neurons directly but also disinhibits them by reducing 
GABA release from striotonigral terminals [167,168]. The 5-HT-induced 
excitation is observed in the majority of the SNr neurons recorded and most 
probably mediated by a direct action on 5-HT2C receptors being blocked by 
ketanserin and ritanserin and mimicked by α–methyl 5-hydroxytriptamine, 
unselective antagonists and agonist of the 5-HT2C receptor subtype, respectively 
[167,168]. In addition, Góngora-Alfaro and colleagues’ in vitro study revealed that 
5-HT can excite about half of SNr neurons tested, this effect was seen in the 
neurons and blocked by methysergide, thus confirming the involvement of 5-HT2C 
receptors [169]. These authors also showed a direct 5-HT-inhibitory action on SNr 
neurons probably mediated by 5-HT1 receptors [169]. Consistent with these 
findings, we showed that mCPP excites SNr neurons by activating 5-HT2C 
receptors in vivo [110]. This effect was evident both after systemic administration 
and local microiontophoretic application of mCPP. Although mCPP is not a 
selective 5-HT2C agonist, because it also acts on other 5-HT receptor subtypes, its 
effects on neurons in the SNr are mediated by the 5-HT2C receptor, inasmuch as SB 
242084, a potent and selective 5-HT2C antagonist, completely blocks the excitation 
elicited by mCPP. An interesting finding of our study was the differential effect 
exerted by mCPP on subpopulations of SNr neurons. Thus, mCPP caused a 
marked excitation of the so-called P(0) non-DA neurons in the SNr, whereas it did 
not affect the P(+) neurons. These neurons are identified on the basis of the 
presence P(+) or the absence P(0) of an excitatory response to a noxious stimulus 
(footpinch). There is evidence that P(+) neurons in the SNr are GABAergic 
interneurons that exert a direct inhibitory influence on DA neurons in the SNc, 
whereas P(0) cells represent SNr projection neurons. Thus, mCPP caused a marked 
excitation of presumed SNr projection neurons but did not modify the SNr 
interneurons firing discharge [110]. It is tempting to speculate that this differential 
response to mCPP might be the basis of the preferential inhibitory effect of 5-HT2C 
agonists on the mesolimbic versus the nigrostriatal dopaminergic function. These 
data have been confirmed by some experiments that are presently under way in our 
laboratory using the most selective agonist and antagonist currently available for 
the 5-HT2C receptor to date. In fact, about 50% of SNr neurons are excited by the 
selective agonist RO 600175 and this effect is counteracted by pre-treatment 
with the new antagonist SB 243213. Microintophoretic application of RO 600175 
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clearly showed a direct effect of the 5-HT2C receptors on the SNr neurons, 
antagonised by SB 243213 applied by pressure ejection (unpublished 
observations).  
 Nevertheless, unilateral microinjection of 5-HT, 5-HT1D agonist, and SSRIs, 
into the SNr of freely moving rats elicited a contraversive circling behaviour 
blocked by systemic pretreatment with methysergide [146,165,170-172]. Current 
theories of circling behaviour hypothesise that the animal turns away from the 
basal ganglia output where activity has been reduced. Taken together this evidence, 
apparently in contradiction with the latest in vivo and in vitro electrophysiological 
studies, suggests that endogenously released 5-HT exerts a predominantly 
inhibitory effect on the SNr output neurons. In order to explain these discrepancies, 
it is possible to argue that 5-HT released in vivo elicits an excitatory response in a 
discrete population of SNr neurons, which in turn inhibits a greater number of 
neighbouring SNr cells through GABA release from their extensive axon 
collaterals [173]. The fact that methysergide inhibited the contraversive circling 
induced by SSRIs nicely fits with the ability of the unselective 5-HT2C receptor 
antagonists to block the excitatory action of 5-HT or 5-HT2C receptor agonists on 
SNr neurons in vitro and in vivo [110,167-169, our unpublished observations]. 
Interestingly, it has been shown that 5-HT2C receptor transmission may be a key 
determinant in the activity of SNr in parkinsonism but not in the “normal” basal 
ganglia. Indeed, intranigral infusion of SB 206553 into the SNr on the unlesioned 
side of 6-hydroxydopamine (6-OHDA)-lesioned rat did not elicit a significant 
rotational response [174]. In keeping with this, there is evidence that a number of 
selective antagonists, SB 200646A, SB 206553 and SB 242084, do not elicit 
locomotory activity when given alone [175-177]. Conversely, infusion of SB 
206553 into the SNr on the 6-OHDA-lesioned side elicited a marked rotational 
response, contraversive to the injection [174]. Such behaviour represents a 
reduction in activity of basal ganglia outputs and can be taken as representing a 
potential anti-parkinsonian action. Moreover, systemic administration of SB 
206553 enhanced the action of D2 agonist quinpirole and D1 agonist SKF 82958 
in eliciting a rotational response contraversive to the lesioned side [174,178]. The 
mechanism whereby 5-HT2C receptor antagonists enhance the anti-parkinsonian 
action of DA receptor agonists may involve reducing the overactivity of the SNr. 
When given alone, 5-HT2C receptor antagonists may only be capable of reducing 
the activity to a certain degree following systemic administration. Therefore, there 
may not be sufficient reduction in the activity of SNr to restore the normal 
thalamo-cortical output and have an overt anti-parkinsonian effect.  
 
Serotonin2C modulation of subthalamic nucleus activity 
 The subthalamic nucleus, is an important mediator of the output circuits 
subserving basal ganglia motor function. It is interposed in the direct pathway 
between  the GPe  and the GPi/SNr. The  STN also has projections that interact  
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with the other primary output pathway from the striatum, the direct pathway, at 
the level of the GPe [179,180]. This connectivity provides the STN with a unique 
ability to mediate basal ganglia motor function, and accordingly, the STN has a 
strong influence on motor behaviour related to basal ganglia DAergic 
neurotransmission [181]. For instance, the STN has been implicated in the 
mediation of Parkinsonian movement disorders. An increase in the basal activity 
of the excitatory glutamatergic afferent neurons of the STN, associated with the 
loss of DA terminals in the striatum, may play a role in the hypokinetic 
symptoms of this condition [182]. Indeed, STN lesion as well as its inactivation 
by deep brain stimulation has shown to have antiparkinsonian effects in primates 
experimental PD model and in PD patients [183-185]. Under normal DA 
function, in both humans and primates, unilateral lesions of the STN result in 
hemiballism and chorea which are characterised by involuntary, hyperkinetic 
movements of the contralateral limbs [186,187]. Serotonin neurons, mainly from 
DRN, innervate the STN, and clearly modulate its neuronal activity. The 5-HT2C 
receptors are most likely involved in 5-HT effects, since they are present in a 
relatively high concentration in this nucleus. The most frequent response to 5-HT 
seems to be an excitation of STN neurons [188-190]. This effect is mediated by 
the activation of the 5-HT2C and 5-HT4 receptors being reversed by the combined 
use of selective antagonists for 5-HT4 and 5-HT2C receptors [189,190]. 
Moreover, an inhibitory action of 5-HT over a small subpopulation (about 20%) 
of STN neurons has been also shown by Stanford et al. [190], and it seems to be 
mediated by 5-HT1A receptors activation [190]. Thus, this electrophysiological 
evidence indicates that 5-HT-induced excitation or inhibition in the STN are 
separate entities and most likely to arise as a consequence of independent, direct 
post-synaptic effects mediated by 5-HT2C, 5-HT4 and 5-HT1A subtypes. 
However, these electrophysiological findings are not in accordance with a large 
body of behavioural evidence which shows an inhibitory action of 5-HT over the 
STN by acting on 5-HT2C receptors. As a result, a decrease in the excitatory 
input from the STN to GPe/SNr occurs, which in turn enhances the activity of 
the ipsilateral motor thalamus. Indeed, the unilateral injection of 5-HT into the 
STN induces a contralateral dose-dependent turning behaviour which is blocked 
by a non selective 5-HT2 antagonist mianserin. The contribution of the 5-HT2C 
receptor in 5-HT-induced behaviour was revealed by the intrasubthalamic 
injection of the 5-HT2C receptor agonist MK 212 that, in concordance, 
increased the net turns [191]. In addition, the blockade of subthalamic 5-HT2C 
receptors suppressed the stereotypic behaviour induced by apomorphine 
administration [192] while both systemic administration and local unilateral 
infusion of m-CPP into the STN induced an increase in oral movements in rats 
[193-195], that resemble the orofacial dyskinesias occurring as a severe side 
effect      of prolonged treatment with antipsychotic drugs in humans  [196,197]. 
Oral dyskinesia observed after peripheral injections of m-CPP was enhanced by  
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5,7-dihydroxytryptamine (5,7-DHT)-induced lesion of the serotonergic neurons, 
probably due to an altered sensitivity to 5-HT2C receptor stimulation in the STN 
[194]. Interestingly, these authors observed m-CPP induced seizure-like 
behaviours in a subset of lesioned rats that were never observed in sham-lesioned 
animals, thus demonstrating a pivotal role for the 5-HT2C receptor in the control 
of the normal neuronal excitability, a phenomenon already noted by others [194]. 
Despite the fact that the mechanism by which serotonergic inputs to the STN 
contribute to its normal functioning remains controversial, the behavioural data 
discussed above clearly suggest that excess stimulation of 5-HT2C receptors in 
this region may lead to hyperkinetic movement disorders. Thus 5-HT2C 
antagonists can be useful to treat the side effects of long-term administration of 
neuroleptics in schizophrenia [198,199].  
 
Serotonin2C receptors in Parkinson’s disease and 
other related motor disorders 
 Since Hornykiewicz’s pioneering work in identifying the SNc as the site of 
major pathological change in PD, reduced dopaminergic innervation of the 
striatum has been thought to be central to its pathogenesis [200]. However, 
relatively little research has been focused on other parts of the dopaminergic 
system and on the influence of other neurotransmitter systems. Nonetheless, 
the fact that several other neurotransmitters, and among them 5-HT, are also 
involved in PD, has long since been known [201-204]. There is no doubt that a 
gradual degeneration of 5-HT neurons occurs in the raphe nuclei in PD. 
Decarboxylase activity has been shown to be reduced in these nuclei in PD 
patients. Further, 5-HT is reduced in ascending pathways as noted by Chase 
and co-workers [205,206]. Indeed, post-mortem examinations have shown a 
reduction of up to 50% of 5-HT in some areas of the cortex and the basal 
ganglia [202,207,208], and antemortem studies have shown reduced 
cerebrospinal fluid levels of the major 5-HT metabolite, 5-hydroxy-indolacetic 
acid (5-HIIA) in PD patients. Recently, imaging studies of PD patients have 
shown decreased activity of 5-HT transporter (5-HTT) in the thalamus, medial 
frontal areas, caudate nucleus and the putamen, indicating a pathophysiological 
involvement of 5-HT in the disease process [209-211]. It is, however, very 
likely that the degree of serotonergic degeneration depends on the stage of the 
disease [204]. No consistent morphologic change has been identified in 
parkinsonian brain stem raphe nuclei [210] but, in primates, surgical lesion of 
upper brainstem producing contralateral resting tremor, and bradykinesia were 
associated with reduced homolateral striatal 5-HT [212].  
 However, preclinical research on animal models of PD has provided 
discrepant results from the above mentioned evidence in humans, highlighting 
that these experimental models only represent an imperfect replica of human 
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disorders [204]. Indeed, it has been shown that DRN serotonergic neurons in 6-
OHDA-lesioned rats fire at an higher frequency and preferentially display 
burst firing activity [213]. Since it has been demonstrated that the consequence 
of the repetitive burst firing pattern for DRN neurons enhances both 5-HT 
release and its postsynaptic effect [214], it is possible to speculate that in rat 6-
OHDA-model of PD, a hyperfunction of the serotonin system occurs. 
According to this hypothesis, several studies have shown a hyperinnervation of 
5-HT nerve terminals in the striatum of rats and mice lesioned with 6-OHDA 
[215-221]. Consistently, striatal 5-HT levels and 5-HTT binding have been 
reported to be increased in this animal model of PD [219,220,222-225]. 
Interestingly, it has been proposed that striatal serotonergic hyperinnervation in 
lesioned animals occurs to compensate for the lost function of DAergic 
terminals, indeed raphe-striatal serotonergic neurons produce DA from 
exogenously administered L-DOPA and release it as “false transmitter” [226]. 
This suggests that 5-HT neurotransmission is impaired and the clarification of 
the mechanism of its striatal hyperinnervation can provide unique information 
regarding the treatment of parkinsonism from a point of view that differs from 
conventional therapy. 
 An additional consequence of neonatal DA depletion is the up-regulation 
of striatal postsynaptic 5-HT receptors. Indeed, it has been shown that the 
inhibitory response of neostriatal neurons to the iontophoretic application of 5-
HT and to the preferential 5-HT2C receptor agonist mCPP is enhanced in 
neonatal 6-OHDA lesioned rats [144]. However, in situ hybridization and 
autoradiographic radioligand studies from lesioned rats and human postmortem 
tissue from patients with PD have revealed that striatal 5-HT2C receptors are 
not influenced by DA depletion, in contrast to 5-HT2A receptors that appear to 
be up-regulated [70,227]. Indeed, mRNA expression and the number of  5-
HT2C receptors is unchanged in this rodent model of PD and in parkinsonian 
patients [70,227]. Fox and colleagues [70] also showed that there was no 
significant difference in 5-HT2C binding level for control versus PD tissue in 
the GPi and GPm. Conversely, 5-HT2C receptor binding in the SNr of aged-
matched control tissue was less than half that in the SNr of patients with PD, 
strictly in accordance with the 50% increase in 5-HT2C receptor binding 
observed in 6-OHDA-lesioned rats [70,228].  
 This evidence highlights a selective change in 5-HT2C receptor activity 
only in the output regions of the basal ganglia. 5-HT2C receptors up-regulation 
might be compensatory, being a consequence of a decreased level of 5-HT in 
this nuclei and thus potentially underlie a role for them in the neuronal 
mechanisms involved in PD [70]. However, the changes in 5-HT2C receptor 
binding reported by Fox and colleagues were seen in PD patients with 
levodopa-induced dyskinesia, it is thus possible that they could be ascribed to 
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the process underlying dyskinesia rather than parkinsonism [70]. Thus, reduced 
stimulation of 5-HT2C receptors would lead to decreased activity of the basal 
ganglia output nuclei and increased levels of abnormal movements. This 
hypothesis may predict an efficacious use of 5-HT2C agonists for alleviating 
the side-effects of long-term treatment with levodopa, although clozapine and 
quetiapine, antagonists for this receptor subtype, have been used successfully for 
this purpose [229]. On the other hand, systemic administration of the selective 5-
HT2C antagonist SB 206553 was shown to enhance the action of the anti-
parkinsonian action of the dopamine D1 and D2 agonists in the 6-
hydroxydopamine-lesioned rats [230,231], suggesting that the use of a 5-HT2C 
receptor antagonist in combination with a dopamine receptor agonist may reduce 
the reliance upon dopamine replacement therapies. Hitherto, no studies have 
been conducted in either non-human primates or humans to address this issue.  
 Another interesting application of the data regarding the functional role of 
5-HT2C receptors in the basal ganglia is the possible use of 5-HT2C receptor 
antagonists in the treatment of drug-induced parkinsonian syndromes. 
Moreover, in addition to the neurodegenarative, idiopathic form, parkinsonian 
symptoms are also produced by typical APDs therapy such as haloperidol, a 
mixed DA antagonist. Conversely, clozapine and other atypical APDs, that 
also have a high affinity to 5-HT2C receptors [232], reduced motor side-effect 
liability because of the same degree of intrinsic antiparkinsonian 
characteristics, which act to counteract the pro-parkinsonian effects of DA 
blockade. This was suggested by early clinical studies indicating that the 5-
HT2A/2C receptor antagonist ritanserin [233,234] can ameliorate negative 
symptoms as well as attenuate exciting extrapiramidal side effects (EPS) in 
schizophrenics treated with classical APDs [235,236]. The relevance of 5-HT2C 
receptor blocking in the effect of atypical APDs was shown by Canton and 
colleagues [237], who revealed the high affinity of clozapine and risperidone 
for 5-HT2C sites in the rat choroid plexus. These findings were subsequently 
confirmed [238-242] and extended to brain sections [241,242], and in 
transiently expressed 5-HT2C receptors [47,243]. Antagonism at 5-HT2C 
receptors by several atypical antipsychotics was also observed in vivo. Indeed, 
clozapine produces an increase in extracellular levels of DA in the nucleus 
accumbens [244,245], reverses the inhibition of accumbal DA release induced 
by the 5-HT2C agonist RO 60175 [244] and blocks the hypolocomotion 
induced by the 5-HT2C agonist mCPP [246].  
 It is worth noting that clozapine, like several atypical APDs, behaves as a 
5HT2C inverse agonist in heterologus expression systems in vitro [247,86,88] 
and in vivo [86]. Thus, the 5-HT2C receptor inverse agonist might underlie the 
unique clinical properties of atypical APDs such as low EPS profile and good 
antidyskinetic efficacy [86,247,229]. 
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 The involvement of 5-HT2C receptor in the neuroleptics EPS disturbance is 
underlined also by the behavioural evidence that clozapine inhibits the 
cataleptic response to loxapine and olanzapine [248] and SB 228357, a 
selective 5-HT2B/2C receptor antagonist reverses haloperidol-induced catalepsy 
[249]. This hypothesis is further reinforced by the observation that the 5-HT2C 
receptor activation by RO 600175 per se induces catalepsy [250].  
 
 It has been suggested that 5-HT2C receptors are also involved in the resting 
tremor that occurs in PD. Parkinsonian resting tremor in humans is usually 
quite focal. The most common tremor seen in patients with PD is a “pill-
rolling” movement of the hands [251]. Despite a number of clinical and basic 
studies, the neural substrate for this motor complication remains unclear. A 
glimmer of light was recently thrown on this, by Carlson and colleagues using 
cholinomimetic-induced jaw movements in the rat as a model of parkinsonian 
tremor [252]. The authors showed that local injections of a mixed 5-HT2A/2C 
receptor antagonist into the SNr block tremulous jaw movements in rat [252]. 
This result is consistent with previous studies showing that the jaw movement 
activity was suppressed potently by clozapine, olanzapine and risperidone 
[253-255] and with clinical reports demonstrating serotonergic involvement in 
the generation and treatment of parkinsonian symptoms and other motor 
dysfunction [256].  
 
 In addition to the possible role of 5-HT2C receptors in regulating movement, 
we have recently suggested that manipulation of 5-HT2C receptor-mediated 
transmission might prove useful in addressing psychiatric problems such 
depression which is often associated to PD [52,257]. Indeed, we have showed 
that 5-HT2C receptor antagonists cause an increase of VTA DA neurons activity 
and in the accumbal DA release [85,124,128], an effect that might be useful in 
treating the comorbid depression that often accompanies PD [258,259].  
 
Conclusions and implications 
 From the large amount of literature here reviewed it is apparent that the 
serotonergic neurotransmitter system plays a pivotal role in the modulation of 
basal ganglia circuitry, and its dysfunction is involved in the pathophysiology 
of PD. Among all the 5-HT receptors present in the basal ganglia nuclei, the 5-
HT2C receptor subtype seems to be one of the principal receptors through 
which 5-HT exerts its function. Twenty five years of 5-HT2C receptors research 
has generated detailed information on the molecular biology and regional and 
cellular localization of these receptors. Furthermore, this research has revealed 
that the 5-HT2C receptor could be a potential target for therapeutic intervention 
in mood disorders, anxiety, stress, sexual dysfunctions, eating disorders, and 
drug abuse. From the above discussion it seems clear that drugs acting at the  
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5-HT2C receptor might be an important feature of the treatment of PD, drug-
related motor disturbances, and the depressive symptoms often associated with 
these neurological disorders.  
 
 Nevertheless, further clarification of the role of 5-HT2C transmission in the 
pathophysiology of basal ganglia disorders is required, since the overall picture 
is still confusing. Furthermore, most of the data came from animal studies and 
animal models of PD that yield contrary results compared to clinical studies. 
This leaves room for speculation about the real value of preclinical research for 
clinical PD. The enthusiasm generated by the research of Fox and colleagues 
[70,174,178,230,231] at the end of the 90’s has been dampened by the lack of 
clinical results to date. Although several selective agents for this receptor have 
been discovered, none have reached the market for the treatment of motor 
disorders as yet. However, several companies are very active in 5-HT receptors 
research in PD, though they have concentrated on different receptor subtypes 
such as 5-HT1A, 5-HT1B/D and 5-HT2A. Moreover, there are also many avenues 
that remain unexplored, so there are undoubtedly further advances to be made. 
In the next few years, we will certainly see compounds selective for 5-HT2C 
receptors making further significant impacts on the treatment of the major 
motor disturbances such as PD.  
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